CureVac wants to skip phase three clinical trials to get a coronavirus vaccine deployed, the German biotech companys supervisory board chair has told Belgian media.
The company, which the Commission offered €80 million to invest in last month, is one of more than 30 companies racing to find a vaccine.
The companys majority shareholder, Dietmar Hopp, has implied a vaccine would be on the market by autumn — a prediction echoed by Commission President Ursula von der Leyen but contradicted by regulators.
“All stages are underway” to start the first phase of clinical trials in June or July, Jean Stéphenne, the newly appointed chair of the companys supervisory board and a former CEO of GlaxoSmithKline Biologicals (now GSK Vaccines), told LEcho in an interview published Thursday.
That phase is the first test on humans and looks at the vaccines safety and dosage.
Afterward, the company plans to move to phase two and test the efficacy of Read More – Source
CureVac wants to skip phase three clinical trials to get a coronavirus vaccine deployed, the German biotech companys supervisory board chair has told Belgian media.
The company, which the Commission offered €80 million to invest in last month, is one of more than 30 companies racing to find a vaccine.
The companys majority shareholder, Dietmar Hopp, has implied a vaccine would be on the market by autumn — a prediction echoed by Commission President Ursula von der Leyen but contradicted by regulators.
“All stages are underway” to start the first phase of clinical trials in June or July, Jean Stéphenne, the newly appointed chair of the companys supervisory board and a former CEO of GlaxoSmithKline Biologicals (now GSK Vaccines), told LEcho in an interview published Thursday.
That phase is the first test on humans and looks at the vaccines safety and dosage.
Afterward, the company plans to move to phase two and test the efficacy of Read More – Source
